The Food and Drug Administration (FDA) has updated its labeling requirements for the HIV drug Prezista (darunavir). Specifically, the FDA has added warnings regarding the potential for liver damage and toxicity to occur in those people using the drug Prezista. Case reports from recent clinical trials indicate that there have been cases of liver damage in people using an HIV medication regimen that included Prezista. Read more in this article from The Body Pro.

Related Information

• Prezista (darunavir) Medication Fact Sheet

• Medication Side Effects & Solutions

• Understand Your HIV Treatment Regimen